Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
https://doi.org/10.37489/2588-0519-2020-3-15-26
Abstract
The prevalence of comorbidity — asthma and atopic dermatitis — is not understood well yet. More severe processes decreasing quality of life and increasing a social-economic burden of disease are occurred in such kind comorbidity.
Aim: an evaluation of economic burden of non-control severe asthma in combination with severe atopic dermatitis in the local conditions.
Materials and methods. Analysis has been performed for adult patients; the bottom-up approach of costs evaluation was used. Direct medical and non-medical as well as indirect costs were calculated for two models: Model 1 — current practice of the treatment, Model 2 — treatment with Dupilumab.
Results. Model 1 — Weighted average expenditures for one patient were 3,1 mln RUR, indirect costs were dominated (76 % from the total), severe atopic dermatitis had 15 % of total. Model 2 (with Dupilumab) — Dupilumab has decreased the total weighted average cost on 903 905 RUR. The total economic burden of comorbidity was 17,6 bln RUR in the current treatment option, and 12,4 bln RUR in Dupilumab hand (different is 5,2 bln RUR, or burden decrease is expected on 29,2 %).
Conclusion. The wider introduction of Dupilumab into clinical practice, which allows achieving control in the treatment of severe asthma and severe atopic dermatitis, should reduce treatment costs and reduce the socio-economic burden of these diseases as a result.
About the Authors
I. S. Krysanov
Medical Institute of Continuing Education, MSUFP;
Institute of Clinical and Economic Assessment and Pharmacoeconomics, JSC;
FSSBI «N.A. Semashko National Research Institute of Public Health»
Russian Federation
Russian Federation
Krysanov Ivan S. - PhD of Pharmaceutical Sciences, Assistant professor, Head of the Department of Pharmacy in Medical Institute of Continuing Education, MSUFP; Leading Researcher in FSSBI «N.A. Semashko National Research Institute of Public Health»
SPIN code: 1290-4976
Moscow
V. S. Krysanova
Medical Institute of Continuing Education, MSUFP;
FSAEI HE I.M. Sechenov First MSMU MOH Russia;
State Budgetary Institution of the Moscow region “Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry”
Russian Federation
Russian Federation
Krysanova Vera S. - MD, PhD student of Department of Clinical pharmacology and Propaedeutics of internal diseases in N.V. Sklifosovsky Institute of Clinical Medicine, Sechenov University; Researcher in SBI of MR «Scientifi c and Practical Center for Clinical and Economic Analysis of Ministry of Health of the Moscow Region», ; Lecture of the Department of Th erapy and Children’s Diseases in Medical Institute of Continuing Education, MSUFP
SPIN code: 6433-2420
Moscow
O. I. Karpov
JSC «Sanofi Russia»
Russian Federation
Russian Federation
Karpov Oleg I. - Dr. MD, PhD Sci. in Medicine, professor, Head of Eurasia HEOR i
Moscow
V. Yu. Ermakova
Department of Pharmacy in A.P. Nelyubin Institute of Pharmacy, Sechenov University, Russia, Moscow; Department of Therapy and Children’s Diseases in Medical Institute of Continuing Education, MSUFP, Russia, Moscow
Russian Federation
Russian Federation
Ermakova Viktoriya Yu. - PhD of Pharmaceutical Sciences, Assistant professor of the Department of Pharmacy in A.P. Nelyubin Institute of Pharmacy, Sechenov University; Lecture of the Department of Therapy and Children’s Diseases in Medical Institute of Continuing Education, MSUFP
SPIN code: 8039-3069
Moscow
References
1. Enilari O, Sinha S. The Global Impact of Asthma in Adult Populations. Annals of Global Health. 2019;85(1):2, 1-7. https://doi.org/10.5334/aogh.2412
2. Aleksandrova GA, Golubev NA, Tyurina EM, i dr. Zabolevaemost’ vsego naseleniya Rossii v 2018 godu. Statisticheskie materialy. CHast’ II. Moscow: Departament monitoringa, analiza i strategicheskogo razvitiya zdravoohraneniya Minzdrava Rossijskoj Federacii, FGBU «CNIIOIZ» Minzdrava Rossijskoj Federacii; 2019. (In Russ). URL: http://mednet.ru/miac/meditsinskaya-statistika Ссылка активна на 11.06.2020.
3. Chuchalin AG. Achievements in the treatment of asthma In Russia in the first decade of the new millennium. Consilium Medicum (Extras). 2010:11-12. (In Russ).
4. Ekspertnyj sovet po zdravoohraneniyu Komiteta Soveta Federacii Rossijskoj Federacii po social’noj politike i zdravoohraneniyu. «Social’noekonomicheskoe bremya bronhial’noj astmy i hronicheskoj obstruktivnoj bolezni legkih v Rossijskoj Federacii». Moscow: 2010. (In Russ).
5. Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015; Suppl 1: S7-10. https://doi.org/10.1002/alr.21547
6. Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2019. pii: S1323-8930(19)30077-2.https://doi.org/10.1016/j. alit.2019.06.003
7. Global’noe bremya boleznej. Voprosy zdravoohraneniya [Internet]. Oficial’nyj sajt Vsemirnoj organizacii zdravoohraneniya (In Russ).] URL: https://www.who.int/topics/global_burden_of_disease/ru Ссылка активна на 05.11.2019.
8. The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network, 2018 [Internet] URL: http://www.globalasthmareport.org/index.html Ссылка активна на 16.05.2020.
9. Karimkhani C, Dellavalle RP, Coff eng LE, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017; 153(5):406-412.https://doi.org/10.1001/jamadermatol.2016.5538
10. Seth D, Cheldize K, Brown D, et al. Burden of Skin Disease: Inequities and Innovations. Curr. Dermatol. Rep. 2017;6(3):204-210. https://doi.org/10.1007/s13671-017-0192-7
11. Ha J, Lee SW, Yon DK. 10-year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008-2017. Clin Exp Pediatr. 2020 Jan 29.https://doi.org/10.3345/cep.2019.01291
12. Price KN, Krase JM, Loh TY, et al. Racial and ethnic disparities in global Atopic Dermatitis clinical trials. Br J Dermatol. 2020 Feb 7. https://doi.org/10.1111/bjd.18938
13. Megna M, Patruno C, Balato A, et al. An Italian multicenter study on adult atopic dermatitis: persistent versus adult-onset disease. Arch Dermatol Res. 2017;309(6):443-452. https://doi.org/10.1007/s00403-017-1739-y
14. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645-1651.https://doi.org/10.1080/03007995.2016.1195733
15. Fomina DS, Serdotetskova SA, Gadzhieva MK, Lutsenko LS. Experience with the Use of Dupilumab as a Part of Complex Treatment of Asthma and Atopic Dermatitis in Adults in Real Clinical Practice: Literature Review and Clinical Cases. Practical pulmonology. 2019:(3);84-92. (In Russ).
16. Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2020.https://doi.org/10.1016/j.jaad.2020.02.055
17. Krysanov IS, Krysanova VS, Karpov OI, Ermakova VYu. Social-economic burden of severe atopic dermatitis in the Russian Federation. Kachestvennaya klinicheskaya praktika. 2019;(4):4-14. (In Russ). https://doi.org/10.1016/2588-05192019-4-14
18. Lee JK, Han D. Atopic dermatitis is an important comorbidity in severe asthma. Annals of Allergy, Asthma & Immunology. 2018;120(6):661-662. https://doi.org/10.1016/j.anai.2018.02.026
19. Silverberg JI, Hanifi n JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. Journal of Allergy and Clinical Immunology. 2013;132(5):1132-1138. https://doi.org/10.1016/j.jaci.2013.08.031
20. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122.https://doi.org/10.1016/S0140-6736(15)00149-X
21. Alhassan S, Hattab Y, Bajwa O, et al. Asthma. Crit Care Nurs Q. 2016;39(2):110-123.https://doi.org/10.1097/CNQ.0000000000000104
22. Revyakina VA, Taganov AV, Kuvshinova ED, et al. Atopic dermatitis, modern strategy in the therapy. Lechashchiy vrach. 2019;(5):32-37. (In Russ).
23. Farnaz T, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy. 2018;3(11):53-61.https://doi.org/10.2147/JAA.S107982. eCollection 2018
24. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Dupixent (MNN Dupilumab) [Internet]. Gosudarstvennyj reestr lekarstvennyh sredstv. (In Russ). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=2d734674-0315-4c6e-8a29-86dacd4f46b7&t= Ссылка активна на 16.05.2020.
25. Gooderham M, Hong HC, Eshtiaghi P, Papp K. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3S1):S28-S36. https://doi.org/10.1016/j.jaad.2017.12.022
26. Corren J, Castro M, Chanez P, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122(1):41-49.e2.https://doi.org/10.1016/j. anai.2018.08.005
27. Busse WW, Maspero JF, Rabe KF, et al. A Randomized, Controlled Phase 3 Study, Liberty Asthma QUEST: Phase 3 randomized, double-blind, placebocontrolled, parallel-group study to evaluate Dupilumab efficacy/safety in patients with uncontrolled, moderateto-severe Asthma. Adv Ther. 2018;35(5):737-748.https://doi.org/10.1007/s12325-018-0702-4
28. Rabe KF, Nair P, Brusselle G. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485. https://doi.org/10.1056/ NEJMoa1804093
29. Order of the Government of the Russian Federation No. 2406-R of October 12, 2019 [Internet]. (In Russ). Доступно по:http://base.garant.ru/72861778 Ссылка активна на 16.05.2020.
30. Zyryanov SK, Dyakov IN, Karpov OI. Modeling of the impact of biological drugs in the economic burden of severe asthma. Kachestvennaya klinicheskaya praktika. 2019;(3):4-12. (In Russ). https://doi.org/10.24411/2588-0519-2019-10078
31. Registr pacientov s tyazheloj bronhial’noj astmoj na territorii RF [Internet]. (In Russ). URL: https://rosmed.info Ссылка активна на 26.11.2018.
32. Metodicheskie rekomendacii po raschetu zatrat pri provedenii kliniko-ekonomicheskih issledovanij lekarstvennyh preparatov. Utverzhdeny prikazom FGBU «CEKKMP» Minzdrava Rossii ot 29 dekabrya 2017 g. №185-od. (In Russ). URL: https://rosmedex.ru/wp-content/uploads/2018/02 Metodicheskie-rekomendatsii-po-raschetu-zatratpriprovedenii-kliniko-e%60konomicheskih-issledovaniylekarstvennyihpreparatov-2017.pdf Ссылка активна на 16.05.2020.
33. Predel’nye razmery optovyh nadbavok i predel’nye razmery roznichnyh nadbavok k cenam na zhiznenno neobhodimye i vazhnejshie lekarstvennye preparaty, ustanovlennye v sub»ektah Rossijskoj Federacii. (In Russ). URL: https://fas.gov.ru/documents/684978 Ссылка активна на 16.05.2020.
34. Salasyuk AS, Frolov MYu, Barykina IN. Dupilumab in the treatment of severe non-controlled bronchial asthma - economic aspects. Kachestvennaya klinicheskaya praktika. 2019;(2):15-24. (In Russ). https://doi.org/10.24411/2588-0519-2019-10063
35. Decree of the Government of the Russian Federation No. 1610 of December 7, 2018 «O programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2020 god i na planovyj period 2021 i 2022 godov» [Internet]. (In Russ). URL: http://government.ru/docs/38547 Ссылка активна на 16.05.2020.
36. Pis’mo Federal’nogo fonda obyazatel’nogo medicinskogo strahovaniya ot 21.02.2020 №2493/26-1/i «Instrukciya po gruppirovke sluchaev, v tom chisle pravila ucheta dopolnitel’nyh klassifi kacionnyh kriteriev, i podhodam k oplate medicinskoj pomoshchi v ambulatornyh usloviyah» [Internet]. Federal’nyj fond obyazatel’nogo medicinskogo strahovaniya. (In Russ). URL: http://www.ff oms.ru/upload/medialibrary/572/5729412a4a0c850186a8a6eaaae87619.pdfСсылка активна на 16.05.2020.
37. Metodicheskie rekomendacii po provedeniyu sravnitel’noj kliniko-ekonomicheskoj ocenki lekarstvennogo preparata (novaya redakciya). Approved by order No. 242-od of the Ministry of health of the Russian Federation dated December 29, 2018 [Internet]. (In Russ). URL: https://rosmedex.ru/wp-content/uploads/2019/06/MRKE`I_novaya-redaktsiya_2018-g..pdf Ссылка активна на 16.05.2020.
38. Luskin AT, Chipps BE, Rasouliyan L, et al. Impact of asthma exacerbations and asthma triggers on asthmarelated quality of life in patients with severe or difficult to treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544-552. https://doi.org/10.1016/j.jaip.2014.02.011
39. Th açi D, L Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266?275.https://doi.org/10.1016/j.jdermsci.2019.02.002
40. Eremina MG. Ocenka vozdejstviya immunozavisimyh dermatozov na kachestvo zhizni lic trudosposobnogo vozrasta. [dissertation] Saratov; 2014. (In Russ). URL: http://www.dslib.net/soc-medicina/ocenkavozdejstvija-immunozavisimyh-dermatozov-na-kachestvo-zhizni-lic.html Ссылка активна на 16.05.2020.
Review
For citations:
Krysanov I.S., Krysanova V.S., Karpov O.I., Ermakova V.Yu. Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(3):15-26. (In Russ.) https://doi.org/10.37489/2588-0519-2020-3-15-26
Views:
2091
Email this article 